• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Eris Lifesciences Q2 net up 35 per cent at Rs 93.14 cr

expressbpdNovember 20, 2017

Tag: Eris , LifeSciences

Consolidated total income of the company also rose to Rs 255.68 crore

Drug firm Eris Lifesciences has reported a 34.51 per cent rise in its consolidated net profit to Rs 93.14 crore for the second quarter ended September 30. The company had posted a net profit of Rs 69.24 crore for the corresponding period of the previous fiscal, Eris Lifesciences said in a filing to BSE. Consolidated total income of the company also rose to Rs 255.68 crore for the quarter under consideration as against Rs 208.08 crore for the same period a year ago.

Previous:Statement by FDA Commissioner Scott Gottlieb, M.D., on efforts to address impact of IV fluid shortag

Next:Strides Shasun divests India brand business to Eris Lifesciences for Rs 500 cr

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Eris Lifesciences Q2 net up 35 per cent at Rs 93.14 cr | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Primula veris root Extract Powder

Primula veris root Extract Powder
Low Maq Coptis Chinensis Berberis Aristata Extract HCL 633-65-8 Berberine Hydrochloride Powder

Low Maq Coptis Chinensis Berberis Aristata Extract HCL 633-65-8 Berberine Hydrochloride Powder
Iberis amara Extract Powder

Iberis amara Extract Powder
Adiantum Capillus Veneris Extract Powder

Adiantum Capillus Veneris Extract Powder
Rhizoma Dryopteris P.E

Rhizoma Dryopteris P.E
High Quality Pure Natural Organic Dryopteris Extract Powder

High Quality Pure Natural Organic Dryopteris Extract Powder
BG-80D Seris High-efficient Film Coating Machine Of Spraying

BG-80D Seris High-efficient Film Coating Machine Of Spraying
ginger powder Zingiber officinale Rosc powder gingembre powder rhizoma zingiberis recens powder

ginger powder Zingiber officinale Rosc powder gingembre powder rhizoma zingiberis recens powder
Rhizoma Dryopteris Extract

Rhizoma Dryopteris Extract
Radix Sileris Extarct

Radix Sileris Extarct

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service